CRSP vs. BEAM

In the year-to-date period, CRSP achieves a -7.80% return, which is significantly higher than BEAM's -36.17% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for CRISPR Therapeutics AG (CRSP) and Beam Therapeutics Inc. (BEAM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current CRSP Sharpe Ratio is -0.59, which is comparable to the BEAM Sharpe Ratio of -0.47. The chart below compares the historical Sharpe Ratios of CRSP and BEAM, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither CRSP nor BEAM has paid dividends to shareholders.

The maximum CRSP drawdown since its inception was -85.11%, roughly equal to the maximum BEAM drawdown of -89.12%. Use the drawdown chart below to compare losses from any high point for CRSP and BEAM.

The current volatility for CRISPR Therapeutics AG (CRSP) is 19.35%, while Beam Therapeutics Inc. (BEAM) has a volatility of 24.72%. This indicates that CRSP experiences smaller price fluctuations and is considered to be less risky than BEAM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between CRISPR Therapeutics AG and Beam Therapeutics Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.